GPN Vaccines

We are delighted to support Carla Gallasch as the University of Adelaide's first PhD student to be awarded a National Industry PhD Program Scholarship! Building on years of know how and learnings from the Gamma-PN program, Carla is working on a new vaccine to provide protection against Haemophilus influenzae - a major cause of ear infections in children.

GPN Vaccines is building its clinical team and is seeking an experienced Clinical Project Manager to work with our Chief Medical Officer. The role can be either full or part-time depending on experience and remote candidates are encouraged to apply. Industry experience is essential, and those with GCP training and a track record of running vaccine studies will be highly regarded.

Team lunches are getting bigger at GPN Vaccines! Celebrating the retirement of Professor James Paton and Leigh Willis who have both made invaluable contributions to the company, and welcoming new staff and students Chloe Gates, Ricky Williams, Brooke Dilmetz, Janice Henrichs and Mariana Couto Moniz.

Congratulations Chloe Gates and welcome (officially) to the team! We look forward to building on the great work you did with us during your PhD as well as working on some exciting new projects!

Congratulations to our Director of Microbiology Dr Erin Brazel for being recognised at the The Australian Society for Microbiology conference with the ASM Industry Engagement Award. The award recognises outstanding contributions by early and mid-career microbiologists working with industry. Erin was invited to deliver the ASM Industry Engagement Award Lecture and described progress on GPN Vaccines’ lead product, Gamma-PN.

Our CEO Tim Hirst moderated the opening session of the 20th Annual Congress of International Drug Discovery, Science & Technology Europe held on 17 June 2024 in Budapest. Tim gave a keynote talk on “The Quest for Universal Vaccines". #IDDST24

Big news! We are very excited to announce the closing of an oversubscribed AUD$18 million Series B1 investment round. The strong support we received from current and new investors is testament to the value of a broad-spectrum pneumococcal vaccine that protects against both current and emerging serotypes. This new funding will be used to support further clinical development of Gamma-PN, as well as our pipeline of innovative vaccines against other bacterial pathogens. Many thanks to Yolanda Redrup for the article and Headshots Adelaide for the photo! https://lnkd.in/e9H-TS4X.

Please share with your networks! We are particularly interested in scientists with industry experience and can offer a competitive salary package, a highly respected and collaborative global team, and of course some exciting science!

We are pleased to announce the award of AUD$936,000 to GPN Vaccines in Round 3 of the CUREator Program! This funding will be used to support investigation of the durability of Gamma-PN's immune response in adults. Thank you to Brandon Capital and supporters CSIRO and Australian Government Department of Health and Aged Care for this important funding.

For anyone attending The World Vaccine Congress in Washington DC next week, be sure to drop into the AMR Workshop on Monday 1st April to see our CEO Tim Hirst give a talk highlighting the need for a serotype-independent pneumococcal vaccine.